Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: A Monte Carlo simulation

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 534-542

  Frymoyer, Adam ^a   Hersh, Adam L ^a   Coralic, Zlatan ^b   Benet, Leslie Z ^c   Joseph Guglielmo, B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c San Francisco   (United States)

Author keywords

Methicillin resistant Staphylococcus aureus; Monte Carlo simulation; Pediatrics; Pharmacokinetics pharmacodynamics; Vancomycin

Indexed keywords

METICILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG TARGETING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PREDICTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; LIKELIHOOD FUNCTIONS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 77951899851     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.005     Document Type: Article

References (31)

1. Vancocin (vancomycin injection) [package insert] 2003, Baxter Healthcare Corporation, Deerfield, Ill.
2. The Harriet Lane Handbook: A Manual for Pediatric House Officers 2005, Mosby, Philadelphia, Pa. 17th ed. J. Robertson, N. Shilkofski (Eds.).
3. Taketomo CK, Hodding JH, Kraus DM Lexi Comp's Pediatric Dosage Handbook with International Trade Names Index: Including Neonatal Dosing, Drug Administration, & Extemporaneous Preparations (Lexi-Comp's Drug Reference Handbooks) 2007, Lexi-Comp, Hudson, Oh. 14th ed.
4. Principles and Practice of Pediatric Infectious Diseases 2008, Churchill Livingstone Elsevier, Philadelphia, Pa. 3rd ed. S.S. Long, L.K. Pickering, C.G. Prober (Eds.).
5. Schaad UB, McCracken GH, Nelson JD Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr. 1980, 96:119-126.
6. Chang D Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995, 14:667-673.
7. Lamarre P, Lebel D, Ducharme MP A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother. 2000, 44:278-282.
8. Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit. 2000, 22:522-531.
9. Burke RE, Halpern MS, Baron EJ, Gutierrez K Pediatric and neonatal Staphylococcus aureus bacteremia: Epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol. 2009, 30:636-644.
10. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis. 2009, 49:65-71.
11. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis. 2005, 40:1785-1791.
12. Purcell K, Fergie J Epidemic of community-acquired methicillinresistant Staphylococcus aureus infections: A 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med. 2005, 159:980-985.
13. Vancomycin. Basic Clinical Pharmacokinetics 2004, 451-476. Lippincott Williams & Wilkins, Philadelphia, Pa. 4th ed. P. Ambrose, M.E. Winter (Eds.).
14. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004, 43:925-942.
15. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists [published correction appears in Am J Health Syst Pharm. 2009;66:887]. Am J Health Syst Pharm. 2009, 66:82-98.
16. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009, 28:398-402.
17. Bradley JS, Dudley MN, Drusano GL Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003, 22:982-992.
18. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Crow Aerobically; Approved Standard 2009, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, Pa. 8th ed.
19. Glover ML, Cole E, Wolfsdorf J Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care. 2000, 15:1-4.
20. Steinkraus G, White R, Friedrich L Vancomycin MIC creep in non-VISA, vancomycin susceptible clinical MRSA blood isolates from 2001-2005. Program and Abstracts of the 106th Annual Meeting of the American Society for Microbiology 2006, American Society for Microbiology, Orlando, Fla. Washington, DC, Abstract A-084.
21. Wang G, Hindler JF, Ward KW, Bruckner DA Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006, 44:3883-3886.
22. Sakoulas G, Moellering RC Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008, (Suppl 5):S360-S367.
23. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005, 171:388-416. American Thoracic Society/Infectious Diseases Society of America.
24. Sakoulas G, Eliopoulos GM, Moellering RC, et al. Staphylococcus aureus accessory gene regulator (agr) group II: Is there a relationship to the development of intermediatelevel glycopeptide resistance?. J Infect Dis. 2003, 187:929-938.
25. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007, 51:1089-1091.
26. Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillinresistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006, 57:699-704.
27. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med. 2006, 166:2138-2144.
28. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004, 42:2398-2402.
29. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008, 46:193-200.
30. Lodise TP, Lomaestro B, Graves J, Drusano GL Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Anti-microb Agents Chemother. 2008, 52:1330-1336.
31. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009, 49:507-514.